Abiopharma

(99% Neutral) INHIBRX, INC. (INBX) Announces Business Combination

(99% Neutral) INCYTE CORPORATION (INCY) Files Form 8-K

(99% Neutral) Genmab (GMAB) Files Form 6-K

(80% Positive) AC Immune Ltd (ACIU) Announces Clinical Development Update (Form 6-K)

(19% Negative) Cytokinetics, Incorporated (CYTK) Announces Delay in Specified Development Timeline Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(85% Positive) AKERO THERAPEUTICS, INC. (AKRO) Announces Enrollment Update for study Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review

(10% Negative) SUTRO BIOPHARMA, INC. (STRO) Announces Delay in opportunities Trials for our management to predict all risks Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(99% Neutral) GERON CORPORATION (GERN) Announces Executive Departure

(99% Neutral) INTELLIA THERAPEUTICS, INC. (NTLA) Announces Regulatory Update

(99% Neutral) REGENERON PHARMACEUTICALS, INC. (REGN) Announces Regulatory Update